Window of Opportunity Study Targeting the Inflammatory Milieu

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the effect of two anti-inflammatory drugs, fish oil capsules and the COX-2 inhibitor celecoxib, on pregnancy associated breast cancer (PABC). Short-term intervention with anti-inflammatory medications will demonstrate a reduction in the inflammation and immune suppressive phenotype of PABC, and decreased metastatic potential in PABC. This unique window in breast cancer management serves as a valuable opportunity to obtain preliminary data on biomarkers and the alterations that occur when the system is troubled by a drug or other intervention which will be instrumental in designing future therapeutic or preventative strategies for larger clinical study.

Clinical Trial Description

This randomized pilot clinical trial studies omega-3 fatty acid or celecoxib in treating patients with breast cancer planning to undergo surgery. Omega-3 fatty acid may stimulate the immune system in different ways and stop tumor cells from growing. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether omega-3 fatty acid or celecoxib is more effective in treating breast cancer. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01881048
Study type	Interventional
Source	University of Colorado, Denver
Contact
Status	Active, not recruiting
Phase	Early Phase 1
Start date	December 8, 2009
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01987726` - Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
Completed	`NCT01881230` - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)	Phase 2/Phase 3
Terminated	`NCT01918306` - GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer	Phase 1/Phase 2
Terminated	`NCT01705340` - Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery	Phase 1
Terminated	`NCT01222377` - Endoscopic Breast Surgery in Treating Patients With Breast Cancer	N/A
Completed	`NCT00602043` - F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer	Phase 2
Completed	`NCT00100750` - Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer	Phase 1/Phase 2
Completed	`NCT00244881` - A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)	Phase 2
Completed	`NCT00096109` - Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer	Phase 2
Completed	`NCT00425672` - ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment	Phase 1/Phase 2
Completed	`NCT00096434` - Sorafenib in Treating Patients With Metastatic Breast Cancer	Phase 2
Completed	`NCT00057941` - Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer	Phase 2
Terminated	`NCT02892734` - Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer	Phase 2
Recruiting	`NCT03213041` - Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer	Phase 2
Completed	`NCT02015559` - Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus	Phase 2
Completed	`NCT02728596` - S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)	N/A
Completed	`NCT03364348` - 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer	Phase 1
Completed	`NCT02897375` - Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors	Phase 1
Completed	`NCT01672684` - Phase I: At-Home Support for Rural Women Using Group Video Calling	Phase 1
Terminated	`NCT01217411` - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer	Phase 1